Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compare / BPC-157 vs GHK-Cu

BPC-157 vs GHK-Cu

Two peptides sold online with similar claims but different histories. What each one is, how FDA treats it, what human evidence exists and the risks FDA has raised.

Side-by-side facts · No recommendation · Reviewed

BPC-157GHK-CuSame for both

BPC-157GHK-Cu
TypeSynthetic peptideCopper-binding peptide
Promoted forInjury recovery and gut healthSkin care; more recently sold for injection
FDA statusNot approved for any use. Flagged for safety concerns in 2023Not approved as a drug. FDA flagged the injectable form in 2023
Advisory committeeNarrowly recommended for the compounding list in July 2026 (advisory only)Review expected before the end of February 2027
Human evidencePublished data cover only a few dozen peopleSome evidence for topical use on skin; no human studies support injecting it
Evidence gradeBothD
Main risk notedLong-term safety in people is unknownFDA cited a risk of immune reactions with injectable products

What the evidence shows

Almost all of the evidence for BPC-157 comes from animal and laboratory studies. Published human data cover only a few dozen people.

For GHK-Cu there is some human evidence for topical use on skin. No human studies support injecting it.

How FDA treats them

Neither is approved. FDA flagged both in 2023. In July 2026 an advisory committee narrowly recommended adding BPC-157 to the list of substances pharmacies may compound. The vote is advisory, it is not FDA approval, and nothing changes legally until FDA finishes rulemaking. A committee review of GHK-Cu is expected before the end of February 2027.

Risks

Products sold online as research use only have no assurance of identity, dose or sterility. For injectable GHK-Cu, FDA has cited a risk of immune reactions because of possible aggregation and impurities. BPC-157 is banned in sport at all times under the World Anti-Doping Code.

Questions

Is BPC-157 or GHK-Cu FDA approved?

Neither is approved for any use as a drug. FDA flagged both in 2023.

Is topical GHK-Cu different from injectable GHK-Cu?

Yes. The human evidence that exists is for topical use on skin. No human studies support injecting it, and FDA has flagged the injectable form.

Which one is safer?

Neither has been shown to be safe or effective for injection in people. This page compares published facts and does not recommend either.

Which compound, if any, suits a person is a decision for them and a licensed prescriber. This page compares published facts and does not recommend either.

Sources: AJMC: FDA panel backs 6 peptides for compounding; Pharmacy Times: what the peptide vote changes; FDA: bulk drug substances that may present significant safety risks; Worst Pills, Best Pills: unapproved peptides; Black Health: what the FDA peptide vote changed; HHS: enforcement discretion policy for compounding certain peptides (draft); Federal Register: HHS draft peptide compounding policy, October 30, 2026.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.